Bosulif: protein kinase inhibitor for chronic myeloid leukaemia

Bosulif (bosutinib) is indicated in chronic, accelerated or blast phase Philadelphia chromosome positive chronic myeloid leukaemia (CML) previously treated with one or more tyrosine kinase inhibitors and where imatinib, nilotinib and dasatinib are not appropriate.

Bosulif (bosutinib) is licensed for chronic myeloid leukaemia (blood cells from bone marrow in a case of CML, pictured) | SCIENCE PHOTO LIBRARY
Bosulif (bosutinib) is licensed for chronic myeloid leukaemia (blood cells from bone marrow in a case of CML, pictured) | SCIENCE PHOTO LIBRARY


Bosutinib is a protein kinase inhibitor which inhibits the abnormal Bcr-Abl kinase that promotes CML.1


Bosutinib was evaluated in a phase I/II open-label study involving 570 patients with chronic, accelerated or blast phase, imatinib-resistant or imatinib-intolerant CML that had been previously treated with at least one tyrosine kinase inhibitor.1

Marketing approval was granted primarily on the basis of findings in 52 patients deemed as having an unmet medical need because other tyrosine kinase inhibitors were not appropriate due to resistance or the risk of adverse effects. Of these, 36 had chronic phase CML and 16 had either accelerated or blast phase CML.1

In patients with chronic phase CML treated previously with imatinib only, 59% (95% CI 52.9-65.0) achieved a major cytogenetic response (MCyR) at week 24 (primary efficacy endpoint). This compared with 40.9% (95% CI 31.6-50.7) of those treated previously with imatinib and dasatinib or nilotinib.1

In patients with accelerated or blast phase CML treated previously with at least imatinib, the proportions achieving MCyR at week 24 were 34.8% (95% CI 23.7-47.2) and 29.6% (95% CI 18.0-43.6), respectively.1

The most commonly reported adverse effects were GI upset, thrombocytopenia, rash, anaemia, pyrexia and raised serum ALT. 1

Bosulif has been given conditional marketing approval pending further evidence of clinical benefit and safety.


  1. Bosulif Summary of Product Characteristics, March 2013

View Bosulif drug record

Further information: Pfizer

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Iclusig: new protein kinase inhibitor for leukaemia

Iclusig: new protein kinase inhibitor for leukaemia

Iclusig (ponatinib) is a protein kinase inhibitor that...

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases